
"Sector" = median of Healthcare across 84 companies
Danaher Corporation is a global science and technology innovator headquartered in Washington, D.C., operating in the healthcare sector with a focus on diagnostics and research. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. Its portfolio spans life sciences, diagnostics, environmental and applied solutions, serving customers in hospitals, laboratories, and research institutions worldwide.
Danaher generates revenue primarily through the sale of instruments, consumables, software, and services across three segments: Life Sciences (e.g., chromatography, mass spectrometry), Diagnostics (e.g., clinical chemistry, immunoassays, molecular diagnostics), and Environmental & Applied Solutions (e.g., water quality, product identification). The company's business model emphasizes recurring revenue from consumables and services, supported by a strong innovation pipeline and strategic acquisitions.
In the highly competitive diagnostics and research industry, Danaher competes with companies like Thermo Fisher Scientific, Abbott Laboratories, and Roche. It holds a leading position in several niche markets, such as water quality analysis and dental imaging, and benefits from a diversified portfolio that mitigates sector-specific risks. Its strong margins and consistent cash flow generation underscore its competitive advantage.
Danaher's primary customers include clinical laboratories, hospitals, pharmaceutical and biotech companies, academic research institutions, and industrial manufacturers. Geographically, revenue is well-diversified: North America accounts for roughly 45%, Europe 25%, Asia-Pacific 20%, and the rest of the world 10%. The company's global footprint and exposure to secular growth trends in healthcare and life sciences underpin its long-term demand.
An auto-generated descriptive profile based on company data, for informational purposes only.
Danaher's stock declined 0.58% to 203.83 USD, reflecting continued bearish sentiment. Recent news highlights include the StatLab Medical Products acquisition to expand diagnostics, and multiple analyses suggesting the stock may trade at a discount despite a five-year decline. Jim Cramer publicly advised against owning Danaher, while implied volatility surged on options. The upcoming earnings report is a key catalyst, with expectations of another beat.
Latest saved period: March 2026 · 2026-03-31
Cash dividends by ex-date, not an investment recommendation.
| Ex-date | Amount | Payment date | Period |
|---|---|---|---|
| Mar 27, 2026 | $0.40 | Apr 24, 2026 | Quarterly |
| Dec 26, 2025 | $0.32 | Jan 30, 2026 | Quarterly |
| Sep 26, 2025 | $0.32 | Oct 31, 2025 | Quarterly |
| Jun 27, 2025 | $0.32 | Jul 25, 2025 | Quarterly |
| Mar 28, 2025 | $0.32 | Apr 25, 2025 | Quarterly |
| Dec 27, 2024 | $0.27 | Jan 31, 2025 | Quarterly |
| Sep 27, 2024 | $0.27 | Oct 25, 2024 | Quarterly |
| Jun 28, 2024 | $0.27 | Jul 26, 2024 | Quarterly |
| Mar 27, 2024 | $0.27 | Apr 26, 2024 | Quarterly |
| Dec 28, 2023 | $0.24 | Jan 26, 2024 | Quarterly |
| Oct 11, 2023 | $0.27 | Oct 27, 2023 | Quarterly |
| Jun 29, 2023 | $0.24 | Jul 28, 2023 | Quarterly |
| Mar 30, 2023 | $0.24 | Apr 28, 2023 | Quarterly |
| Dec 29, 2022 | $0.22 | Jan 27, 2023 | Quarterly |
| Sep 29, 2022 | $0.22 | Oct 28, 2022 | Quarterly |
| Jun 23, 2022 | $0.22 | Jul 29, 2022 | Quarterly |
| Mar 24, 2022 | $0.22 | Apr 29, 2022 | Quarterly |
| Dec 29, 2021 | $0.19 | Jan 28, 2022 | Quarterly |
| Sep 29, 2021 | $0.19 | Oct 29, 2021 | Quarterly |
| Jun 24, 2021 | $0.19 | Jul 30, 2021 | Quarterly |
| Mar 25, 2021 | $0.19 | Apr 30, 2021 | Quarterly |
| Dec 24, 2020 | $0.16 | Jan 29, 2021 | Quarterly |
| Sep 25, 2020 | $0.16 | Oct 30, 2020 | Quarterly |
| Jun 25, 2020 | $0.16 | Jul 31, 2020 | Quarterly |
Wrqti brings Danaher Corporation data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Companies in the Healthcare sector you can compare with Danaher Corporation:
When available, the page shows quarterly and annual statements plus ratios such as PE, price to book, profit margin, and free cash flow. Latest financial period shown: March 2026.
Wrqti content depends on available data and third-party sources and may include delays or errors. Review official company filings and consult a licensed financial advisor before making investment decisions. Read the data methodology.